Table 3.

Univariate and multivariate analyses for progression-free survival and overall survival.

Variable (comparator)	Progression-free survival				Overall survival
	Univariate		Multivariate		Univariate		Multivariate
	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value
Treatment (none)
5FU+anti-EGFR	0.55 (0.42–0.73)	<0.001	0.59 (0.44–0.77)	<0.001	0.49 (0.34–0.70)	<0.001	0.55 (0.38–0.81)	0.002
Anti-EGFR	0.73 (0.53–0.99)	0.048	0.71 (0.51–0.98)	0.039	0.64 (0.43–0.93)	0.021	0.67 (0.45–1.01)	0.051
5FU	0.63 (0.31–1.28)	0.629	0.75 (0.36–1.56)	0.435	0.50 (1.83–1.35)	0.171	0.78 (0.28–2.20)	0.641
WBC count (normal)
High	1.42 (1.11–1.82)	0.006	1.31 (0.99–1.73)	0.062	1.87 (1.38–2.53)	<0.001	1.55 (1.11–2.19)	0.011
ALP (normal)
High	1.30 (0.97–1.75)	0.076	1.07 (0.77–1.49)	0.691	1.87 (1.33–2.63)	<0.001	1.35 (0.92–1.97)	0.122
ECOG-PS (0)
1–2	1.13 (0.89–1.43)	0.387	1.07 (0.83–1.37)	0.619	1.43 (1.07–1.92)	0.016	1.17 (0.85–1.61)	0.342
No. of met. sites (1)
≥2	1.31 (1.03–1.65)	0.025	1.20 (0.93–1.53)	0.158	1.63 (1.20–2.21)	0.002	1.39 (1.01–1.92)	0.046
Sex (male)
Female	1.01 (0.80–1.28)	0.924	1.02 (0.80–1.3)	0.891	0.88 (0.65–1.18)	0.389	0.83 (0.61–1.14)	0.254
Age (non-elderly)
Elderly (≥70 years)	0.99 (0.77–1.29)	0.984	1.10 (0.83–1.45)	0.515	1.32 (0.95–1.83)	0.093	1.43 (1.01–2.02)	0.047

5-FU, 5-fluorouracil; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group—Performance Status; ALP, alkaline phosphatase; WBC, white blood cell.